|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Galectin-3 (Gal-3) and suppression of tumorigenicity 2 (ST2) induce fibrotic alterations in severe MR and heart failure.
|
29896861 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study evaluates the prognostic value of repeated time-dependent galectin-3 measurements in acute HF patients.
|
29187387 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (ST2) are very interesting biomarkers for heart failure and myocardial fibrosis.
|
31622239 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings show that although an excess of cardiac and systemic Gal-3 is present in patients with HF of hypertensive origin, this molecule is not associated with histological, molecular and biochemical parameters related to myocardial fibrosis in these patients.
|
25684565 |
2015 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We undertook metabolomic and lipidomic phenotyping of a cohort of heart failure (HF) patients and utilized Multiple Regression Analysis (MRA) to identify associations to CPET and HFBio test performance (peak oxygen consumption (Peak VO2), oxygen uptake efficiency slope (OUES), exercise duration, and minute ventilation-carbon dioxide production slope (VE/VCO2 slope), as well as the established HF biomarkers of inflammation C-reactive protein (CRP), beta-galactoside-binding protein (galectin-3), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)).
|
31220103 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is involved in fibrosis and heart failure.
|
31772609 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, inhibition of galectin‑3 by intravenous tail vein injection of a galectin‑3‑targeting short hairpin RNA‑expressing vector during hypertension‑induced heart failure in Dahl hypertensive rats increased rat survival and body weight.
|
29286090 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We are presenting an electrochemical immunosensor for the determination of Galectin-3 (Gal-3), a biomarker of heart failure.
|
29096363 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Circulating galectin-3 (Gal-3) is elevated and significantly correlates with all-cause and cardiovascular mortality in patients with heart failure.
|
30477951 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
CT-1 (cardiotrophin-1) and Gal-3 (galectin-3) are increased in HF and associated with myocardial fibrosis.
|
30612490 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We sought to find whether galectin-3 has a prognostic value in patients with heart failure and a reduced left ventricular ejection fraction undergoing ablation of persistent atrial fibrillation.
|
30067817 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), indicating cardiac fibrosis, is a documented biomarker of prognosis in HF.
|
28318874 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 was not associated with either HF with reduced EF or HF with preserved EF.
|
31645163 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Using a random-effects meta-analysis, we found an HR of 1.10 (95% CI 1.05 to 1.14) for all-cause mortality, 1.22 (95% CI 1.05 to 1.39) for CVD mortality, and 1.12 (95% CI 1.04 to 1.21) for HF risk for each 1 SD increase in galectin-3 level.
|
28247849 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cardiac (NT-proBNP, cTnI, sST2,Gal-3) and inflammatory (IL-6,IL-8) biomarkers were determined in plasma collected from 12 paediatric patients and 7 adult patients with HF, before and at 4 h,1,3,7,14 and 30 days after VAD implant.
|
30040920 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased galectin-3 plasma concentration has been linked to an unfavorable outcome in patients with heart failure or atrial fibrillation (AF).
|
29118378 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
|
30372548 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3, a β-galactoside binding lectin, has been described as a mediator of cardiac fibrosis in experimental studies and as a risk factor associated with cardiovascular events in subjects with heart failure.
|
26312551 |
2015 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Salivary Gal-3 concentrations were significantly higher (p < 0.05) in patients with HF who subsequently experienced the primary endpoint compared to those who did not.
|
31598750 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 has been implicated in cardiac and renal fibrosis and serves as a prognostic clinical indicator in heart failure.
|
29417184 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is an independent predictor of poor outcomes and mortality in patients with heart failure (HF).
|
29180917 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is known as a key fibroblasts activating factor which is involved in the fibrogenesis of several diseases, such as pulmonary fibrosis, vascular fibrosis, and heart failure.
|
28826890 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, α1-antitrypsin and lectin-like oxidized low-density-lipoprotein receptor-1 seem to represent two good markers in HF and therapeutic targets, whereas galectin-3 does not.
|
31782085 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure.
|
26277636 |
2015 |